Ilsung Is Co., Ltd. (KRX:003120)

South Korea · Delayed Price · Currency is KRW

20,800

-50 (-0.24%)

Nov 13, 2026, 3:30 PM KST

Market Cap	144.95B -9.2%
Revenue (ttm)	65.22B -5.2%
Net Income	5.54B -52.2%
EPS	787.04 -53.8%
Shares Out	6.97M
PE Ratio	26.43
Forward PE	n/a
Dividend	1,500.00 (7.21%)
Ex-Dividend Date	Dec 29, 2026

Volume	9,536
Open	21,000
Previous Close	20,850
Day's Range	20,700 - 21,200
52-Week Range	17,120 - 29,300
Beta	-0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Ilsung Is

Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular sys... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1954

Country South Korea

Stock Exchange Korea Stock Exchange

Ticker Symbol 003120

Full Company Profile

Financial Performance

In 2025, Ilsung Is's revenue was 64.29 billion, a decrease of -6.85% compared to the previous year's 69.02 billion. Earnings were 1.17 billion, a decrease of -91.10%.

Financial Statements